Two Sigma Securities’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,095
Closed -$17K – 2067
2026
Q2
$17K Sell
1,095
-777
-42% -$8.58K ﹤0.01% 1507
2026
Q1
$12.1K Buy
+1,872
New +$17.6K ﹤0.01% 1447
2024
Q2
– Sell
-77
Closed -$5.61K – 3314
2024
Q1
$5.61K Buy
77
+13
+20% +$956 ﹤0.01% 2826
2023
Q4
$5.36K Buy
+64
New +$6.21K ﹤0.01% 2876
2022
Q2
– Sell
-4
Closed -$17K – 2520
2022
Q1
$17K Buy
+4
New +$21K ﹤0.01% 1996

Other funds holding MTRI

Two Sigma Securities's MTRI Position: Q3 2026 in Review

Two Sigma Securities sold out of Mentari Therapeutics, Inc. Common Stock (MTRI) in Q3 2026, closing a stake of 1,095 shares — an estimated $17K sold.

Two Sigma Securities first reported a position in MTRI in Q1 2022 and held it in 5 quarters. The position peaked at $17K in Q1 2022. 16 funds tracked by Wall St. Rank hold MTRI as of Q3 2026.

  • Two Sigma Securities reported no remaining Mentari Therapeutics, Inc. Common Stock position as of Q3 2026 after selling out during the quarter.
  • Two Sigma Securities sold 1,095 Mentari Therapeutics, Inc. Common Stock shares in Q3 2026, an estimated $17K.
  • Two Sigma Securities first reported a position in Mentari Therapeutics, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • Two Sigma Securities's Mentari Therapeutics, Inc. Common Stock position peaked at $17K in Q1 2022.
  • 16 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2026.

Based on Two Sigma Securities's 13F filing for Q3 2026, filed 16 Nov 2026.